Clinical and laboratory characteristics as well as risk factors of the HSCT cohort
| HSCT n=61 | Group A CMV (−) n=22 | Group B CMV (+) n=19 | Group C CMV colitis n=20 | P value A versus B | P value A versus C |
| Gender (M/F), n (%) | 14/8 (64/36) | 11/8 (58/42) | 10/10 (50/50) | 0.76 | 0.53 |
| Age (mean, SD) | 51.5 (13.3) | 52.9 (12.1) | 51.2 (11.2) | 0.65 | 0.67 |
| Haemoglobin, g/dL (mean, SD) | 10 (±2) | 10 (±4) | 9 (±1) | 0.94 | 0.76 |
| Thrombocyte, cells ×103/µL (mean, SD) | 123 (±106) | 135 (±87) | 128 (±74) | 0.54 | 0.61 |
| Leucocyte, cells ×103/µL (mean, SD) | 6 (±6) | 6 (±4) | 6 (±3) | 0.35 | 0.39 |
| CRP, mg/dL (mean, SD) | 56 (±45) | 78 (±78) | 74 (±72) | 0.59 | 0.56 |
| Endoscopic ulcers, n (%) | 2 (9) | 4 (21) | 13 (65) | 0.39 | 0.0003*† |
| GVHD, n (%) | 3 (14) | 4 (21) | 3 (15) | 0.68 | 0.98 |
Medication, n (%)
| 17 (77) 19 (86) 8 (36) 2 (9) | 13 (68) 17 (90) 7 (37) 2 (11) | 14 (70) 20 (100) 2 (10) 3 (15) | 0.73 0.98 0.99 0.98 | 1.74 0.23 0.07 0.66 |
| Number of immunosuppressive medications >2 | 7 (32%) | 4 (21%) | 16 (80%) | 0.50 | 0.002*‡ |
Immunosuppressants: tacrolimus, ciclosporine A, everolimus, sirolimus.
Others: rituximab, alemtuzumab, thalidomide.
*Corrected for Bonferroni.
†OR of endoscopic ulcer group A versus C: 18.6 (95% CI 3.3 to 103.7).
‡OR of number of immunosuppressive medications >2 group A versus C: 8.6 (95% CI 2.1 to 35.3).
CMV, cytomegalovirus;CRP, C-reactive protein;GVHD, graft versus host disease;HSCT, haematopoietic stem cell transplantation;MMF, mycophenolate mofetil.